Aβ misfolding and clinical Alzheimer’s disease status

The introduction of UHF scanners allowed to identify radiological signs in neurodegenerative disorders, previ- ously undetectable at magnetic fields ≤ 3 T: the detec- tion of

Since a recent study suggested an increase in immunoproteasome gene expression during aging and in microglia associated with Aβ-plaques in APP/PS1 mice [88], we

Using sponsor’s models, reviewer conducted additional simulations to (a) predict the effect of dose staggering (for example, administering ibrutinib 2 hours before the

Dose adjustment for patients with mild and moderate renal or hepatic impairment is not recommended based on population PK analyses; however, such patients should be closely

Although no change was observed on the total lenvatinib expoure (AUC 0-inf, total ) in patients with mild, moderate, and severe renal impairment as compared to normal

O-linked N-acetylglucosamine (O-GlcNAc) has been extensively studied in the context of Alzheimer disease (AD) but the potential role(s) of this posttranslational

Neuropsychopharmacology, v.. Takashima, 2010, Aggregation of detergent-insoluble tau is involved in neuronal loss but not in synaptic loss: Journal of Biological Chemistry,

A novel concept for the treatment of such diseases is the so-called “chaperone mediated therapy” which applies specific small active site directed molecules, such as